![]() alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol structure
|
Common Name | alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol | ||
---|---|---|---|---|
CAS Number | 105565-56-8 | Molecular Weight | 348.39000 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C18H22F2N4O | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanolBMY 14802 is a sigma-1 receptor (σ1R) antagonist, as well as an agonist at serotonin (5-HT) 1A and adrenergic alpha-1 receptors. BMY 14802 inhibits abnormal involuntary movement (AIM) in rat Parkinson's disease (PD) model, with down-regulating the expression of AIM[1][2]. |
Name | 4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]-1-(4-fluorophenyl)butanol |
---|---|
Synonym | More Synonyms |
Description | BMY 14802 is a sigma-1 receptor (σ1R) antagonist, as well as an agonist at serotonin (5-HT) 1A and adrenergic alpha-1 receptors. BMY 14802 inhibits abnormal involuntary movement (AIM) in rat Parkinson's disease (PD) model, with down-regulating the expression of AIM[1][2]. |
---|---|
Related Catalog | |
Target |
Sigma 1 Receptor 5-HT1A Receptor α1-adrenergic receptor |
In Vivo | BMY 14802 (15 mg/kg;腹腔注射;单次剂量) 在大鼠 PD 模型中显著抑制 AIM 并减少运动障碍,尤其是在处理后的第一个小时[1][2]。 |
References |
Molecular Formula | C18H22F2N4O |
---|---|
Molecular Weight | 348.39000 |
Exact Mass | 348.17600 |
PSA | 52.49000 |
LogP | 2.39350 |
1-[4-(4-fluorophenyl)-4-hydroxybutyl]-4-(5-fluoropyrimidin-2-yl)-piperazine |
α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine-butanol hydrochloride |
BMS-181100 |
α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol monohydrochloride |
BMY-14802 |
BMY 14802 |
1-(4-Fluoro-phenyl)-4-[4-(5-fluoro-pyrimidin-2-yl)-piperazin-1-yl]-butan-1-ol |